Literature DB >> 10232785

Polymerase chain reaction reveals Trypanosoma cruzi infection suspected by serology in cutaneous and mucocutaneous leishmaniasis patients.

M G Chiaramonte1, F M Frank, G M Furer, N J Taranto, R A Margni, E L Malchiodi.   

Abstract

The existence of patients suffering a double infection caused by Trypanosoma cruzi and Leishmania spp. has been suggested by several authors. Since the conventional serological tests now available for the diagnosis of Chagas' disease lack specificity due to the cross-reactivity between these two parasites, a serological confirmation of a T. cruzi infection cannot be made unless specific antigens are used. An enzyme linked immunosorbent assay (ELISA) to detect antibodies against a specific T. cruzi antigen, named Ag163B6, and immunoblotting using T. cruzi epimastigotes, are non-conventional serological techniques that could be employed for specific diagnosis of Chagas' disease. Using these two methods 34 cutaneous or mucocutaneous leishmaniasis patients were classified into two groups: (A) patients with serological evidence of T. cruzi infection, i.e. those who tested positive in at least one assay (18/34); and (B) patients with no serological evidence of T. cruzi infection, i.e. those who were negative for both assays (16/34). Taking into account the difficulties of xenodiagnosis and its low sensitivity (less than 50%) for a direct diagnosis in the chronic period of the disease, we used polymerase chain reaction (PCR) to confirm a T. cruzi infection in those leishmaniasis patients who presented positive results with the non-conventional serological techniques. Of the 18 patients with serological evidence of T. cruzi infection, 17 gave positive results when genomic DNA primers were used. Using minicircle primers, 15/18 of that group were positive. Nevertheless, all the patients suspected of being double infected were positive in at least one PCR test. Just one patient with no serological evidence of T. cruzi infection gave a positive PCR result when amplifying the minicircle sequence. The proof of the existence of a T. cruzi infection by PCR in leishmaniasis patients suspected to be chagasic when non-conventional serology was used, strongly supports the use of the specific Ag163B6 and immunoblotting with epimastigotes as specific serological diagnostic tools to determine a T. cruzi infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10232785     DOI: 10.1016/s0001-706x(99)00005-4

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  11 in total

1.  Trypanocidal and leishmanicidal activities of sesquiterpene lactones from Ambrosia tenuifolia Sprengel (Asteraceae).

Authors:  Valeria P Sülsen; Fernanda M Frank; Silvia I Cazorla; Claudia A Anesini; Emilio L Malchiodi; Blanca Freixa; Roser Vila; Liliana V Muschietti; Virginia S Martino
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

2.  PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy.

Authors:  Lúcia M C Galvão; Egler Chiari; Andréa M Macedo; Alejandro O Luquetti; Simonne A Silva; Ana Lúcia S S Andrade
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

Review 3.  ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis.

Authors:  Pedro E A A Brasil; Liane De Castro; Alejandro M Hasslocher-Moreno; Luiz H C Sangenis; José U Braga
Journal:  BMC Infect Dis       Date:  2010-11-25       Impact factor: 3.090

4.  Epidemiology of American Tegumentary Leishmaniasis and Trypanosoma cruzi Infection in the Northwestern Argentina.

Authors:  Carlos L Hoyos; Silvana P Cajal; Marisa Juarez; Jorge D Marco; Anahí M Alberti D'Amato; Melina Cayo; Irma Torrejón; Rubén O Cimino; Patricio Diosque; Alejandro J Krolewiecki; Julio R Nasser; José F Gil
Journal:  Biomed Res Int       Date:  2016-09-29       Impact factor: 3.411

Review 5.  Tegumentary leishmaniasis and coinfections other than HIV.

Authors:  Dalila Y Martínez; Kristien Verdonck; Paul M Kaye; Vanessa Adaui; Katja Polman; Alejandro Llanos-Cuentas; Jean-Claude Dujardin; Marleen Boelaert
Journal:  PLoS Negl Trop Dis       Date:  2018-03-01

6.  Natural terpenoids from Ambrosia species are active in vitro and in vivo against human pathogenic trypanosomatids.

Authors:  Valeria P Sülsen; Silvia I Cazorla; Fernanda M Frank; Laura C Laurella; Liliana V Muschietti; Cesar A Catalán; Virginia S Martino; Emilio L Malchiodi
Journal:  PLoS Negl Trop Dis       Date:  2013-10-10

Review 7.  Commercial enzyme-linked immunosorbent assay versuspolymerase chain reaction for the diagnosis of chronic Chagas disease: a systematic review and meta-analysis.

Authors:  Pedro Emmanuel Alvarenga Americano do Brasil; Rodolfo Castro; Liane de Castro
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-01       Impact factor: 2.743

8.  Detection of IgG Anti-Leishmania Antigen by Flow Cytometry as a Diagnostic Test for Cutaneous Leishmaniasis.

Authors:  Geraldo Pedral-Sampaio; Jessé S Alves; Albert Schriefer; Andréa Magalhães; Roberto Meyer; Marshall J Glesby; Edgar M Carvalho; Lucas P Carvalho
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240

9.  Effects of Meglumine Antimoniate Treatment on Cytokine Production in a Patient with Mucosal Leishmaniasis and Chagas Diseases Co-Infection.

Authors:  Karine Rezende-Oliveira; Cesar Gómez-Hernández; Marcos Vinícius da Silva; Rafael Faria de Oliveira; Juliana Reis Machado; Luciana de Almeida Silva Teixeira; Lúcio Roberto Cançado Castellano; Dalmo Correia; Virmondes Rodrigues
Journal:  Trop Med Infect Dis       Date:  2020-05-02

10.  American tegumentary leishmaniasis diagnosis using L. (V.) braziliensis fixed promastigotes: a comparative performance of serological tests and spontaneous cure identification.

Authors:  Andresa Pereira Oliveira Mendes; Beatriz Coutinho Oliveira; Allana Maria S Pereira; Maria Carolina Accioly Brelaz Castro; Marina Assis Souza; Maria Edileuza Felinto Brito; Fernanda Fortes Araújo; Andrea Teixeira-Carvalho; Olindo Assis Martins-Filho; Valeria Rêgo Alves Pereira
Journal:  BMC Infect Dis       Date:  2019-11-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.